


Attorney Docket No.: PB60755USw

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A compound of formula (I);



wherein:


Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl;

R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocycl ring;


R³ is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocycl group, an unsubstituted or substituted C₃₋₈ cycloalkyl group, an unsubstituted or substituted straight or branched C₁₋₁₀ alkyl, an unsubstituted or substituted C₅₋₇ cycloalkenyl, R⁵ or R³ is an optionally substituted 5- to 6-membered aromatic heterocycl group, or group A:



Attorney Docket No.: PB60755USw

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstituted C_{1-6} alkyl, $COCH_3$, or SO_2Me ;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2 , O , S , SO or SO_2 ;

R^6 is halo, an substituted or unsubstituted (C_{1-6})alkyl, substituted or unsubstituted (C_{3-6})cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and R^{10} is hydrogen or R^{10} is halo, an substituted or unsubstituted (C_{1-6})alkyl, substituted or unsubstituted (C_{3-6})cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and R^6 is hydrogen:

R^7 is OH , C_{1-6} alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$, $SOqR^9$;

R^{8a} is H or C_{1-6} alkyl;

R^{8b} is H or C_{1-6} alkyl;

R^9 is C_{1-6} alkyl;

R^{12} is hydrogen or C_{1-6} alkyl;


q is 0, 1 or 2;

R_a can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

R_b can be independently be selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$ or $NHCOOC_{1-6}$ alkyl;

or a pharmaceutically acceptable derivative thereof.

2. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ia):



Attorney Docket No.: PB60755USw

wherein;

R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocycl group, an unsubstituted or substituted C_{3-8} cycloalkyl group or a straight or branched C_{1-6} alkyl group;

R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;


R^{12} is hydrogen or C_{1-6} alkyl;

d is 0, 1, 2 or 3;

m is 0 or 1;

or a pharmaceutically acceptable derivative thereof.

3. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ib):



wherein;

R^3 is an optionally substituted 5- to 6- membered aromatic heterocycl group, or group A;

R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

R^{12} is hydrogen or C_{1-6} alkyl;


d is 0, 1, 2 or 3;

m is 0 or 1;

or a pharmaceutically acceptable derivative thereof.

4. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ic):

Attorney Docket No.: PB60755USw



wherein;

R¹ and R² together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocycl ring;

R⁶ is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

R¹¹ is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

R¹² is hydrogen or C₁₋₆alkyl;

d is 0, 1, 2 or 3;

or a pharmaceutically acceptable derivatives thereof.

5. Canceled.

6. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in ~~any one of~~ claims 1 to 5 or 2 or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.

7. (Original) A pharmaceutical composition as claimed in claim 6 further comprising a second therapeutic agent.

8. (Original) A pharmaceutical composition as claimed in claim 7 wherein the second therapeutic agent is a PDE4 inhibitor.

9. (Currently Amended) A method of treating a mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in ~~any one of~~ claims 1 to 5 or a pharmaceutically acceptable derivative thereof.

Attorney Docket No.: PB60755USw

10. (Currently Amended) A compound of formula (I) as claimed in ~~any one~~ of claims 1 to 5 or a pharmaceutically acceptable derivative thereof for use as a medicament in the treatment of pain.

11. (New) A pharmaceutical composition as claimed in claim 7 wherein the second therapeutic agent is a Cox-2 inhibitor.

12. (New) The method of claim 9 wherein the condition is selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.